2 results about "Halcinonide" patented technology

The invention discloses a short-contact washing agent for treating scalp seborrheic dermatitis and bacterial folliculitis, and relates to the technical field of external preparations and scalp care, the short-contact washing agent comprises the following components by weight: an active component combination: 0.01-0.05 wt% of halcinonide; 0.5 to 1.0 wt% of piroctone ethanolamine; 0.1 to 0.3 wt% of total alkaloids of sophora flavescens; 0.05 to 0.1 wt% of berberine; standardized traditional Chinese medicine effective part extracts are compounded with modern active ingredients, and the problem that the quality difference between batches of traditional Chinese medicine lotion is large is solved. The combination of a plurality of active components aims to synergistically act on a plurality of targets such as anti-inflammation, antibiosis and oil control, so as to comprehensively improve the scalp condition. In addition, the specific semi-solid colloid dosage form improves the staying performance of the product on the scalp, and aims to improve the refreshing feeling after use while ensuring the cleaning effect. The lotion provides a hormone-containing and hormone-free double-version design, and provides choices for requirements of different severity degrees and different use stages.

The present disclosure provides a culture medium for cell culturing, the culture medium containing a combination of specific components. The present disclosure provides a culture medium which contains a combination of components selected from the group consisting of: (1) a halcinonide component; (2) an ALK4 / 7 inhibitor or a TGFβ receptor type-1 kinase inhibitor; (3) a BRD7 / 9 double degradation factor or a BRD7 / 9 binding molecule (degradation factor); (4) an LATS1 / 2 inhibitor, a PKA inhibitor, or an AKT1 inhibitor; (5) a CK1 / 2 inhibitor, an insulin receptor inhibitor, a Tyr kinase inhibitor, a PKA inhibitor or a PKC inhibitor, or an adenosine kinase inhibitor; (6) an E-selectin inhibitor, a VCAM1 inhibitor, or an ICAM1 inhibitor; and (7) an LATS1 inhibitor + an LATS2 inhibitor.